Auditory neurotoxicity and hepatotoxicity after MSMA (monosodium methanarsenate) high dose oral intake.
De Capitani
E M
EM
Poison Control Centre, Hospital de Clínicas, University of Campinas, São Paulo, Brazil. capitani@fcm.unicamp.br
Vieira
R J
RJ
Madureira
P R
PR
Mello
S M
SM
Kira
C S
CS
Soubhia
P C
PC
Toledo
A S
AS
D000328:Adult; D000931:Antidotes / Q000627:therapeutic use; D001151:Arsenic / Q000652:urine; D020261:Arsenic Poisoning / Q000473:pathology* / Q000523:psychology*; D001152:Arsenicals; D001299:Audiometry; D001663:Bilirubin / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury / Q000201:enzymology / Q000473:pathology*; D016057:Evoked Potentials, Auditory, Brain Stem / Q000187:drug effects; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000175:diagnosis; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008099:Liver / Q000201:enzymology; D008111:Liver Function Tests; D008297:Male; D020258:Neurotoxicity Syndromes / Q000473:pathology* / Q000523:psychology*; D013406:Suicide, Attempted
D000931:Antidotes; D001152:Arsenicals; C020300:monomethylarsonic acid; D001151:Arsenic; D001663:Bilirubin